268 related articles for article (PubMed ID: 15575056)
1. Mutation of CEBPA in familial acute myeloid leukemia.
Smith ML; Cavenagh JD; Lister TA; Fitzgibbon J
N Engl J Med; 2004 Dec; 351(23):2403-7. PubMed ID: 15575056
[TBL] [Abstract][Full Text] [Related]
2. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
3. A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
Nanri T; Uike N; Kawakita T; Iwanaga E; Mitsuya H; Asou N
Genes Chromosomes Cancer; 2010 Mar; 49(3):237-41. PubMed ID: 19953636
[TBL] [Abstract][Full Text] [Related]
4. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
6. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
7. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
8. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
11. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
12. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.
Renneville A; Mialou V; Philippe N; Kagialis-Girard S; Biggio V; Zabot MT; Thomas X; Bertrand Y; Preudhomme C
Leukemia; 2009 Apr; 23(4):804-6. PubMed ID: 18946494
[No Abstract] [Full Text] [Related]
13. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
[TBL] [Abstract][Full Text] [Related]
14. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
[TBL] [Abstract][Full Text] [Related]
15. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
16. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
[TBL] [Abstract][Full Text] [Related]
17. Familial myelodysplasia and acute myeloid leukaemia--a review.
Owen C; Barnett M; Fitzgibbon J
Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
[TBL] [Abstract][Full Text] [Related]
18. [Detection of CCAAT/enhancer binding protein alpha gene mutations in acute myeloid leukemia].
Zhao JM; Wang HW; Xu ZF; Zhu L; Bai B; Ge XY
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):299-302. PubMed ID: 15949295
[TBL] [Abstract][Full Text] [Related]
19. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
Juhl-Christensen C; Bomberg M; Melsvik D; Hokland P; Nyvold CG
Eur J Haematol; 2008 Oct; 81(4):273-80. PubMed ID: 18616509
[TBL] [Abstract][Full Text] [Related]
20. Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes.
Carmichael CL; Wilkins EJ; Bengtsson H; Horwitz MS; Speed TP; Vincent PC; Young G; Hahn CN; Escher R; Scott HS
Br J Haematol; 2010 Aug; 150(3):382-5. PubMed ID: 20456351
[No Abstract] [Full Text] [Related]
[Next] [New Search]